BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £273.0m
Enterprise Value £139.6m
Revenue £11.6m
Position in Universe th / 1832

BUZZ-CASI Pharma: Rises on deal with BioInvent to develop, market cancer drug

Tue 27th October, 2020 3:34pm
** Drugmaker's shares  CASI.O  rise 13.6% to 3-month high of
$2.05
    ** CASI signs deal with Sweden-based drug developer
BioInvent International AB  BINV.ST  to develop BINV's cancer
antibody BI-1206 and market it in Greater China region
 urn:newsml:reuters.com:*:nPn4nMPfma
    ** Under terms of agreement, BINV and CASI will develop
BI-1206 in both liquid and solid cancers
    ** CASI responsible for commercialization in China and
associated markets - cos
    ** BioInvent will receive a $5 mln upfront payment and is
eligible to receive up to $83 mln in milestone payments plus
tiered royalties on net sales of BI-1206 
    ** BI-1206 is BioInvent's lead drug candidate being tested
for the treatment of solid tumors and Non-Hodgkin's lymphoma in
combination with other drugs
    ** More than 1.14 bln CASI shares traded, 5x their 25-day
moving avg
    ** Up to Monday's close, stock down 41.8% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.